Experience | Leaflets | Medicines | Patient+ | News | Products | Other
This is a PatientPlus article. PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.
Neuroleptic Malignant Syndrome
Post your experienceSynonyms: NMS, malignant neuroleptic syndrome
This is a rare but potentially life-threatening idiosyncratic reaction to neuroleptic drugs. It causes fever, muscular rigidity, altered mental status and autonomic dysfunction. Although the syndrome is usually associated with potent neuroleptics such as haloperidol and fluphenazine, other drugs or changes in drug regimen that antagonise central dopamine D2 receptors may occasionally cause it. The underlying pathological abnormality is thought to be central D2 receptor blockade or dopamine depletion, in the hypothalamus and nigrostriatal/spinal pathways. This leads to an elevated temperature set-point, impairment of normal thermal homeostasis and extrapyramidally-induced muscle rigidity. The condition shares many features with the serotonin syndrome and malignant hyperpyrexia. It presents a diagnostic challenge.
- Incidence is very low and probably falling because of decreased use of older antipsychotics, preventive measures and an increase in awareness.1
- The exact incidence is difficult to calculate but is estimated to range from 0.02 to 2.4% with conventional antipsychotics, and a much lower incidence for atypical antipsychotics.2
- A large Chinese randomised controlled trial showed an incidence of 0.12% of patients taking neuroleptics, and an Indian study gave a similar incidence of 0.14%.3
- Incidence is higher in those under 40 years old, probably reflecting use of antipsychotics.3
Risk factors for developing NMS:
|
Symptoms
- NMS is most common after initiation or increase in dosage of neuroleptic therapy and in 90% of cases this occurs within 10 days.1
- The onset is usually gradual over 1 to 3 days and tends to occur within 4 weeks of starting or increasing neuroleptic medication. However, it can occur at any time in those taking neuroleptics.
- Symptoms can persist for up to 5 to10 days after discontinuation of offending drug, or longer if depot medication.
- There is always a history of taking neuroleptics or other relevant agents within the last 4 weeks.
- Patients may report dyspnoea (due to hypoventilation caused by muscle rigidity), dysphagia or difficulty walking with the development of a shuffling gait.
- There may be increasing tremor or involuntary movements.
- Rarely there may be oculogyric crises, opisthotonos, seizures or chorea.
Signs
- There will be hyperthermia with temperature > 38°C.
- Muscular rigidity (lead-pipe type) will always be present.
- There is likely to be an alteration in mental status with confusion or agitation and altered consciousness.
- Autonomic instability may manifest as pallor, tachycardia, fluctuating BP, excessive sweating/salivation, tremor and incontinence.
Diagnostic features of Neuroleptic Malignant Syndrome:1
|
- Simple dystonic/akathisia reaction to neuroleptics (usually responds rapidly to anti-cholinergics)
- Serotonin syndrome
- Malignant hyperpyrexia
- Recreational drug toxicity, especially cocaine, amphetamines, MDMA (ecstasy)
- Phenothiazine-related heat stroke (no rigidity and absence of sweating, the cause of pyrexia in this condition)
- Lethal catatonia (rare psychiatric syndrome – catatonia with rigidity ± raised CK, usually no autonomic involvement or involuntary movement)
- Organophosphorous poisoning
- Heat stroke
- Encephalitis (including herpes simplex encephalitis and rabies)
- Hyperthermic reaction to monoamine oxidase inhibitors
- Polymyositis
- Rhabdomyolysis
- Other forms of poisoning (for example strychnine)
- Other drug toxicity (anticholinergics, selective serotonin reuptake inhibitors)
- Full blood count often shows leucocytosis.
- Urea and electrolytes may show metabolic disturbance due to acidosis or renal failure.
- Arterial blood sample to assess acid-base balance.
- Liver function tests may show elevated transaminases and lactate dehydrogenase (LDH) of muscle origin.
- Creatine kinase is usually elevated.
- Urine myoglobin should be checked.
- Coagulation studies (particularly prothrombin time, activated partial thromboplastin time and international normalised ratio or INR) should be checked (to detect coagulopathy).
- A urinary drug screen should be performed (particularly for salicylates, cocaine and amphetamines).
- If sepsis is suspected then blood and other relevant cultures should be taken.
- Imaging may be indicated:
- CXR should be considered if sepsis suspected.
- CT of head in order to exclude other diagnoses.
- Lumbar puncture may be required to exclude other diagnoses (particularly where there is fever and altered mental status). There are no significant CSF findings in NMS other than raised protein.
- Airway and breathing need to be protected if evidence of compromise. Severe cases may require circulatory and ventilatory support.
- Agitated patients require intravenous benzodiazepines. Physical restraint is best avoided or minimised as it can worsen the hyperthermia.
- The offending drug should be discontinued.
- Intravenous fluids should be given for dehydration.
- If there has been a recent overdose of the agent then activated charcoal may help to prevent absorption.
- Cooling devices and antipyretics are used to treat hyperthermia.
- If rhabdomyolysis and renal failure occur then acidification of urine and dialysis is often required.
- Dopaminergic drugs such as bromocriptine and amantadine, and muscle relaxants such as dantrolene sodium are frequently used in severe cases, but there is little empirical evidence for their efficacy. However, there are many anecdotal reports of their usefulness.
- ECT is sometimes used if medication fails to improve condition and there appears to be some evidence to support its use.11,12,13
- Overall prognosis appears to be improving as a result of earlier recognition and intervention.
- The mortality is difficult to estimate because of under-reporting but is thought to be as high as 20%.3
- If renal failure occurs then mortality can be as high as 50%.1
- The outlook is good on the whole if there is:
- Early recognition of the condition
- Adequate supportive care and treatment
- No complications
- Cardiac arrest
- Rhabdomyolysis
- Renal failure
- Seizures
- Respiratory failure
- Disseminated Intravascular Coagulation
- Aspiration pneumonitis
- Deterioration in psychiatric condition due to drug withdrawal
- Infection
- Hepatic failure
- Pulmonary embolism
- Awareness of condition and consideration of the diagnosis in those with relevant symptoms on neuroleptics is central to early diagnosis.
- Monitoring for features of the syndrome after changes in neuroleptic medication can assist early diagnosis.
- Early diagnosis and withdrawal of offending drug will arrest development of worsening symptoms.
- It is important to give a warning of the risk of recurrence. Patients should be actively encouraged to inform healthcare providers of their susceptibility and given good written information to assist in this process. There is a very good case for use of a Medic Alert pendant.
Document references
- Benzer T; Neuroleptic Malignant Syndrome. Emergency medicine perspective. eMedicine, September 2007.
- Ananth J, Parameswaran S, Gunatilake S, et al; Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry. 2004 Apr;65(4):464-70. [abstract]
- Tonkonogy J; Neuroleptic Malignant Syndrome. Psychiatric perspective. eMedicine, May 2006.
- Stotz M, Thummler D, Schurch M, et al; Fulminant neuroleptic malignant syndrome after perioperative withdrawal of antiParkinsonian medication. Br J Anaesth. 2004 Dec;93(6):868-71. Epub 2004 Sep 17. [abstract]
- Gordon PH, Frucht SJ; Neuroleptic malignant syndrome in advanced Parkinson's disease. Mov Disord. 2001 Sep;16(5):960-2. [abstract]
- Ong KC, Chew EL, Ong YY; Neuroleptic malignant syndrome without neuroleptics. Singapore Med J. 2001 Feb;42(2):85-8. [abstract]
- Serrano-Duenas M; Neuroleptic malignant syndrome-like, or--dopaminergic malignant syndrome--due to levodopa therapy withdrawal. Clinical features in 11 patients. Parkinsonism Relat Disord. 2003 Jan;9(3):175-8. [abstract]
- Ward C; Neuroleptic malignant syndrome in a patient with Parkinson's disease: a case study. J Neurosci Nurs. 2005 Jun;37(3):160-2. [abstract]
- Mizuno Y, Takubo H, Mizuta E, et al; Malignant syndrome in Parkinson's disease: concept and review of the literature. Parkinsonism Relat Disord. 2003 Apr;9 Suppl 1:S3-9. [abstract]
- Kuno S, Mizuta E, Yamasaki S; Neuroleptic malignant syndrome in parkinsonian patients: risk factors. Eur Neurol. 1997;38 Suppl 2:56-9. [abstract]
- Scheftner WA, Shulman RB; Treatment Choice in Neuroleptic Malignant Syndrome. Convuls Ther. 1992;8(4):267-279. [abstract]
- Ozer F, Meral H, Aydin B, et al; Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome. J ECT. 2005 Jun;21(2):125-7. [abstract]
- Davis JM, Janicak PG, Sakkas P, et al; Electroconvulsive Therapy in the Treatment of the Neuroleptic Malignant Syndrome. Convuls Ther. 1991;7(2):111-120. [abstract]
DocID: 2508
Document Version: 22
DocRef: bgp25090
Last Updated: 22 Aug 2008
Review Date: 22 Aug 2010
The authors and editors of this article are employed to create accurate and up to date content reflecting reliable research evidence, guidance and best clinical practice. They are free from any commercial conflicts of interest. Find out more about updating.
Related pages in Patient UK
Your Experience (^ top of page)
Please add your experience about this condition / medicineHealth Topic information leaflets related to this topic (^ top of page)
Medicine & Drug information leaflets related to this topic (^ top of page)
PatientPlus articles related to this topic (^ top of page)
Patient UK Newspaper (^ top of page)
Recent related news items
All news by related topic
Related Products (^ top of page)
Medical equipment
Books
Other - Useful resources (^ top of page)
Pictures, diagrams, photos, images, etc.Evidence based medicine
Online textbooks and journals
UK Guidelines
Online Videos
Medline
Other good health sites
Want to search some more? Use the Google Search box below to search our site.
Disclaimer: Patient UK has no control over the content of any external links above. Inclusion does not imply endorsement by Patient UK.
Want to advertise on this site? Find out how >>
Here you can follow a link to view existing patient experiences on this subject, or to add your own
This will offer you the usual PDF options i.e. document navigation, search, zoom and formatted print
Note: this is the best way to print the document
Note: this will open in a new window
Note: this will open in a new window
Here you can follow a link to view existing patient experiences on this subject, or to add your own
This will offer you the usual PDF options i.e. document navigation, search, zoom and formatted print
Note: this is the best way to print the document
Note: this will open in a new window
Note: this will open in a new window



